Sanofi
- Country
- 🇫🇷France
- Ownership
- Public
- Employees
- 87.9K
- Market Cap
- $141.3B
- Website
- http://www.sanofi.com
- Introduction
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.
Evaluation of the Relationship Between ABCG2 Mutation and Teriflunomide Exposure and Safety in Chinese RMS Patients Treated With Teriflunomide 14 mg Once Daily for 24 Weeks
- First Posted Date
- 2020-06-01
- Last Posted Date
- 2022-04-13
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 82
- Registration Number
- NCT04410965
- Locations
- 🇨🇳
Investigational Site Number, China, China
Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1)
- Conditions
- Interventions
- First Posted Date
- 2020-06-01
- Last Posted Date
- 2024-04-19
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 900
- Registration Number
- NCT04410978
- Locations
- 🇺🇸
University of Texas Southwestern Medical Center-Site Number:8400077, Dallas, Texas, United States
🇺🇸Meridian Clinical Research-Site Number:8400003, Savannah, Georgia, United States
🇧🇬Investigational Site Number :1000001, Sofia, Bulgaria
First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL
- First Posted Date
- 2020-05-26
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 47
- Registration Number
- NCT04401020
- Locations
- 🇳🇴
Investigational Site Number : 5780001, Oslo, Norway
🇳🇴Investigational Site Number : 5780101, Oslo, Norway
🇨🇿Investigational Site Number : 2030001, Ostrava - Poruba, Czechia
The Effect of Dupilumab on Lung Inflammation and Related Changes in Airway Volumes Detectable by Functional Respiratory Imaging in Patients With Moderate-severe Asthma
- First Posted Date
- 2020-05-22
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 109
- Registration Number
- NCT04400318
- Locations
- 🇺🇸
Allianz Research Institute Site Number : 8400020, Westminster, California, United States
🇺🇸The Lung Research Center Site Number : 8400010, Chesterfield, Missouri, United States
🇧🇬Investigational Site Number : 1000004, Montana, Bulgaria
Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04)
- Conditions
- Interventions
- First Posted Date
- 2020-05-19
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 31
- Registration Number
- NCT04394624
- Locations
- 🇵🇹
Investigational Site Number : 6200001, Porto, Portugal
🇺🇸Henry Ford Hospital Site Number : 8400005, Detroit, Michigan, United States
🇺🇸Roswell Park Cancer Institute Site Number : 8400003, Buffalo, New York, United States
Study of a Quadrivalent Meningococcal Conjugate Vaccine as a Single Dose Compared With a Single Dose of a Meningococcal Reference Vaccine in Children, Adolescents, and Adults 2 to 55 Years of Age
- Conditions
- Interventions
- First Posted Date
- 2020-04-29
- Last Posted Date
- 2023-09-26
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 360
- Registration Number
- NCT04368429
- Locations
- 🇯🇵
Investigational Site Number 3920001, Koganei-Shi, Japan
🇯🇵Investigational Site Number 3920003, Shinjuku-Ku, Japan
🇯🇵Investigational Site Number 3920004, Nagoya-Shi, Japan
Evaluate the Efficacy and Safety of Rasburicase (Fasturtec®) in the Prevention and Treatment of Hyperuricemia in Pediatric Patients With Non-Hodgkin's Lymphoma and Acute Leukemia
- First Posted Date
- 2020-04-16
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 50
- Registration Number
- NCT04349306
- Locations
- 🇨🇳
investigational site CHINA, China, China
Hydroxychloroquine in Outpatient Adults With COVID-19
- Conditions
- Interventions
- First Posted Date
- 2020-04-03
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 8
- Registration Number
- NCT04333654
- Locations
- 🇺🇸
Investigational Site Number 8400001, Boston, Massachusetts, United States
🇧🇪Investigational Site Number 0561002, Lodelinsart, Belgium
🇫🇷Investigational Site Number 2501001, Bordeaux Cedex, France
Sarilumab COVID-19
- First Posted Date
- 2020-03-31
- Last Posted Date
- 2022-03-17
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 420
- Registration Number
- NCT04327388
- Locations
- 🇦🇷
Investigational Site Number 0320003, Caba, Argentina
🇨🇱Investigational Site Number 1520001, Talca, Chile
🇨🇦Investigational Site Number 1240002, Toronto, Canada
Safety, Pharmacokinetics, and Preliminary Efficacy of Isatuximab in Patients Awaiting Kidney Transplantation
- First Posted Date
- 2020-03-04
- Last Posted Date
- 2023-06-27
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 23
- Registration Number
- NCT04294459
- Locations
- 🇺🇸
Investigational Site Number :8400004, Houston, Texas, United States
🇺🇸Investigational Site Number :8400002, New York, New York, United States
🇺🇸Investigational Site Number :8400001, Rochester, Minnesota, United States